Search results for "102"

showing 10 items of 2892 documents

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct

The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia

2014

OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any …

medicine.medical_specialty2902 Advanced and Specialized NursingEndocrinology Diabetes and Metabolismmedicine.medical_treatment10265 Clinic for Endocrinology and Diabetology610 Medicine & healthContext (language use)law.inventionRandomized controlled triallawInternal medicineDiabetes mellitusInternal MedicinemedicineAdvanced and Specialized NursingCancer preventionInsulin glarginebusiness.industryInsulinCancermedicine.diseaseMetformin2712 Endocrinology Diabetes and MetabolismEndocrinology2724 Internal MedicineNEOPLASIASbusinessmedicine.drugDiabetes Care
researchProduct

A single key-odorant accounts for the pheromonal effect of rabbit milk : Further test of the mammary pheromone's activity against a wide sample of vo…

2003

In the rabbit, lactating females emit a volatile compound in milk, the mammary pheromone (MP), that triggers rooting for the nipple and its grasping in pups. Previous studies have shown that the MP seems to act selectively, in terms both of intensity and quality. Here, we aimed to add new evidence to these properties of the MP. Newborn rabbits (n=825) were submitted to an oral activation test allowing to measure their searching/grasping responses towards different stimuli. In Experiment 1 we assessed whether pups respond to the MP in an intensity-dependent manner. In Experiment 2 we assessed the activity of 20 volatiles previously identified in rabbit milk, other than the MP, which were nev…

medicine.medical_specialtyActivation test[SCCO.NEUR]Cognitive science/Neuroscience05 social sciences[SCCO.NEUR] Cognitive science/NeuroscienceRabbit (nuclear engineering)BiologyChemical communicationBiochemistryAndrology03 medical and health sciences0302 clinical medicineEndocrinologyNature ConservationInternal medicine[ SCCO.NEUR ] Cognitive science/NeurosciencemedicinePheromone0501 psychology and cognitive sciences050102 behavioral science & comparative psychology030217 neurology & neurosurgeryEcology Evolution Behavior and Systematics
researchProduct

Randomized, placebo-controlled, double-blind and open-label studies in the treatment and prevention of acute diarrhea with Enterococcus faecium SF68

2020

Enterococcus faecium SF68® (SF68) is a licensed pharmaceutical for treatment and prevention of diarrhea in Austria, Italy and Switzerland. However, as for other probiotics, evidence for its efficacy is based on small to medium-sized studies. Four unpublished studies on the treatment of acute diarrhea and the prevention of antibiotic-associated diarrhea were analyzed: one randomized, double blind, placebo-controlled trial (RCT) for treatment (n = 1,143), one open-label study for treatment (n = 5,093), one RCT for prevention (n = 1,397) and one open-label study for prevention (n = 4,340). Patients in the treatment-arm and the open-label studies received SF68 (b.i.d. for the prevention studies…

medicine.medical_specialtyAcute diarrheaEnterococcus faecium610 Medicine & health2700 General Medicinerandomized-controlled trialPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialpreventionlawInternal medicinemedicineClinical endpoint030212 general & internal medicineAdverse effectOriginal Researchlcsh:R5-920biologytreatmentbusiness.industryIncidence (epidemiology)SF68acute diarrheaGeneral Medicinebiology.organism_classificationDiarrhea10219 Clinic for Gastroenterology and HepatologyprobioticsMedicine030211 gastroenterology & hepatologymedicine.symptomlcsh:Medicine (General)businessEnterococcus faecium
researchProduct

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

2017

SummaryExisting clinical scores do not perform well in predicting bleeding in elderly patients with acute venous thromboembolism (VTE). We sought to derive an easy-to-use clinical score to help physicians identify elderly patients with VTE who are at high-risk of bleeding during extended anticoagulation (>3 months). Our derivation sample included 743 patients aged ≥65 years with VTE who were enrolled in a prospective multicenter cohort study. All patients received extended anticoagulation with vitamin K antagonists. We derived our score using competing risk regression, with the time to a first major bleeding up to 36 months of extended anticoagulation as the outcome, and 17 candidate var…

medicine.medical_specialtyAnemia2720 Hematology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciencesAnticoagulation0302 clinical medicineElderlyInternal medicineAnticoagulation; Bleeding risk; Elderly; HematologyBleeding riskmedicineDerivation030212 general & internal medicineInternal validation610 Medicine & healthddc:616Framingham Risk Scorebusiness.industry10031 Clinic for AngiologyCancerHematologymedicine.diseaseSurgery10209 Clinic for CardiologybusinessVenous thromboembolismMajor bleeding360 Social problems & social servicesCohort study
researchProduct

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ?

2009

Summary Background:  Statins have emerged as the global leader in pharmacologic therapy for dyslipidaemia, and rosuvastatin has demonstrated clinical efficacy as well as safety in several clinical trials and postmarketing analyses. Aim:  The present article reviewed the effects of rosuvastatin on the quantity and the quality of low-density lipoproteins (LDL). Methods:  We searched for and reviewed all the available evidence in a systematic way. A literature search (by Medline and Scopus) was performed using the following headings: ‘LDL-cholesterol’, ‘LDL size’, ‘LDL subclasses’, ‘small dense LDL’, ‘apolipoprotein B, apo B’ and ‘rosuvastatin’ up to 11 November 2008. The authors also manually…

medicine.medical_specialtyApolipoprotein BHypercholesterolemia10265 Clinic for Endocrinology and DiabetologyMEDLINE610 Medicine & health2700 General MedicinePharmacotherapyInternal medicineDiabetes mellitusmedicineHumansLDL-cholesterolRosuvastatinClinical significanceRosuvastatin CalciumAgedClinical Trials as TopicSulfonamidesbiologybusiness.industrynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseFluorobenzenesPrimary PreventionClinical trialPyrimidinesTreatment OutcomeEndocrinologyCardiovascular Diseasesrosuvastatin LDL-cholesterol type-2 diabetesHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessmedicine.drug
researchProduct

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

2021

Abstract Aims  Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results  The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to eith…

medicine.medical_specialtyCardiac & Cardiovascular SystemsINHIBITIONRATIONALEPlaceboHYPERKALEMIAMECHANISMSHyperkalaemiaChronic kidney diseaseInternal medicineDiabetes mellitusType 2 diabetes mellitusEND-POINTSPost-hoc analysismedicineHumansCanagliflozinRenal Insufficiency Chronic1102 Cardiorespiratory Medicine and HaematologySodium-Glucose Transporter 2 InhibitorsCanagliflozinOUTCOMESScience & Technologybusiness.industryType 2 Diabetes Mellitus1103 Clinical Sciencesmedicine.diseaseCardiovascular System & HematologyDiabetes Mellitus Type 2Serum potassiumCardiovascular System & CardiologyPotassiumCardiology and Cardiovascular MedicinebusinessComplicationLife Sciences & BiomedicineSGLT2 inhibitorsKidney diseasemedicine.drugEuropean Heart Journal
researchProduct

Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee o…

2020

The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activi…

medicine.medical_specialtyCardiologyPhysical activity610 Medicine & healthHeart failureFitness Trackers030204 cardiovascular system & hematologyMedical and Health Sciences2705 Cardiology and Cardiovascular MedicineExercise Capacity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansCardiac and Cardiovascular SystemsIn patientExercise physiologyAssociation (psychology)Set (psychology)ExerciseMonitoring PhysiologicHeart FailureKardiologiPhysical activitybusiness.industryPhysical activity; Activity monitor; Motion sensor; Accelerometer; Heart failuremedicine.diseaseActivity monitor[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAccelerometerHeart failure10209 Clinic for CardiologyMotion sensorPosition paperPosition PaperHuman medicineClinical MedicineCardiology and Cardiovascular MedicineRaw databusinessEuropean Journal of Heart Failure
researchProduct

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

2009

Abstract Objective : Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. Design and Methods We identified 25 subjects with RA (47±8 years, body mass index (BMI) 25±4kg/m 2 ) by the American College of Rheumatology diagnostic criteria, with a disease durations Results As compared to controls RA patients had higher plasma triglycerides (1.8±0.5 vs. 1.0±0.5mmol/L, p p =0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lo…

medicine.medical_specialtyCholesterolbusiness.industry10265 Clinic for Endocrinology and DiabetologyArthritisBlood lipids610 Medicine & healthRheumatoid arthritis small dense LDL HDL-cholesterol Triglyceridesmedicine.disease2705 Cardiology and Cardiovascular MedicineRheumatologychemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineRheumatoid arthritisLow-density lipoproteinmedicineCardiology and Cardiovascular MedicinebusinessaterosclerosiDyslipidemia
researchProduct

An Integrated Framework for Web Services Orchestration

2009

International audience; Currently, Web services give place to active research and this is due both to industrial and theoretical factors. On one hand, Web services are essential as the design model of applications dedicated to the electronic business. On the other hand, this model aims to become one of the major formalisms for the design of distributed and cooperative applications in an open environment (the Internet). In this article, the authors will focus on two features of Web services. The first one concerns the interaction problem: given the interaction protocol of a Web service described in BPEL, how to generate the appropriate client? Their approach is based on a formal semantics fo…

medicine.medical_specialtyComputer Networks and Communicationscomputer.internet_protocolComputer science[ INFO.INFO-WB ] Computer Science [cs]/Web0102 computer and information sciences02 engineering and technologycomputer.software_genre01 natural sciencesBPELWorld Wide WebWeb design0202 electrical engineering electronic engineering information engineeringmedicineWS-AddressingWS-I Basic Profile[INFO.INFO-WB]Computer Science [cs]/WebWEB serviceService-oriented architectureBusiness Process Execution Languagetimed automata equivalence010201 computation theory & mathematics020201 artificial intelligence & image processingWeb serviceWS-PolicyverificationcomputerWeb modelingSoftwareInformation Systems
researchProduct